Literature DB >> 30363548

New Light Shed on Leucine-Rich Repeat Kinase 2 (LRRK2) Kinase Inhibitors in Parkinson's Disease.

Diana A Olszewska1, Tim Lynch1.   

Abstract

Entities:  

Year:  2016        PMID： 30363548      PMCID： PMC6178602          DOI： 10.1002/mdc3.12333

Source DB:  PubMed          Journal:  Mov Disord Clin Pract        ISSN： 2330-1619


× No keyword cloud information.
  5 in total

Review 1.  25 years of small molecular weight kinase inhibitors: potentials and limitations.

Authors:  Doriano Fabbro
Journal:  Mol Pharmacol       Date:  2014-12-30       Impact factor: 4.436

2.  Leucine-rich Repeat Kinase 2 (LRRK2) Pharmacological Inhibition Abates α-Synuclein Gene-induced Neurodegeneration.

Authors:  João P L Daher; Hisham A Abdelmotilib; Xianzhen Hu; Laura A Volpicelli-Daley; Mark S Moehle; Kyle B Fraser; Elie Needle; Yi Chen; Stefanus J Steyn; Paul Galatsis; Warren D Hirst; Andrew B West
Journal:  J Biol Chem       Date:  2015-06-15       Impact factor: 5.157

Review 3.  The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson's disease.

Authors:  Mark R Cookson
Journal:  Nat Rev Neurosci       Date:  2010-11-19       Impact factor: 34.870

4.  Discovery and preclinical profiling of 3-[4-(morpholin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]benzonitrile (PF-06447475), a highly potent, selective, brain penetrant, and in vivo active LRRK2 kinase inhibitor.

Authors:  Jaclyn L Henderson; Bethany L Kormos; Matthew M Hayward; Karen J Coffman; Jayasankar Jasti; Ravi G Kurumbail; Travis T Wager; Patrick R Verhoest; G Stephen Noell; Yi Chen; Elie Needle; Zdenek Berger; Stefanus J Steyn; Christopher Houle; Warren D Hirst; Paul Galatsis
Journal:  J Med Chem       Date:  2014-11-17       Impact factor: 7.446

5.  Genetic basis of Parkinson's disease: inheritance, penetrance, and expression.

Authors:  Claudia Schulte; Thomas Gasser
Journal:  Appl Clin Genet       Date:  2011-06-01
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.